This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
LabCorp (LH) to Enhance Access to OmniSeq INSIGHT via New Program
by Zacks Equity Research
LabCorp's (LH) new sponsored lung cancer program will expand access to comprehensive genomic testing for NSCLC patients to guide informed treatment decisions.
LabCorp (LH) Introduces Latest Assay for Skin Cancer Patients
by Zacks Equity Research
LabCorp's (LH) new assay is claimed to have shown a demonstrable clinical advantage in patients suffering from melanoma.
LabCorp (LH) Debuts At-home Collection Kit for Diabetes Testing
by Zacks Equity Research
LabCorp's (LH) at-home collection kit makes it effortless for consumers to understand their diabetes risk and health status using an innovative and approved collection device.
Here's Why You Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) better-than-expected earnings and robust segmental performance.
LabCorp (LH) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
LabCorp (LH) reports better-than-expected earnings for the first quarter, with robust sales within the Drug Development arm driving the top line.
LabCorp (LH) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 3.91% and 3.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
by Urmimala Biswas
Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
LabCorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Robust base business growth and notable launches are likely to have contributed to LabCorp's (LH) Q1 performance.
LabCorp (LH) Stock Moves -0.57%: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $276.30, moving -0.57% from the previous trading session.
Analysts Estimate LabCorp (LH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $271.14 in the latest trading session, marking a +1.5% move from the prior day.
LabCorp (LH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $264.88, moving +0.24% from the previous trading session.
LabCorp (LH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $263.66, moving -1.99% from the previous trading session.
LabCorp (LH) Gains From Covance Arm Growth, Cost Pressure Ails
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development arm is benefiting from its collaborations with leading pharmaceutical and biotechnology companies.
LabCorp (LH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed the most recent trading day at $273.96, moving +0.93% from the previous trading session.
LabCorp (LH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, LabCorp (LH) closed at $271.44, marking a -0.09% move from the previous day.
Should Value Investors Consider LabCorp (LH) Stock Now?
by Zacks Equity Research
Let's see if LabCorp (LH) stock is a good choice for value-oriented investors right now from multiple angles.
LabCorp (LH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, LabCorp (LH) closed at $274.33, marking a +0.11% move from the previous day.
LabCorp (LH) Stock Moves -0.27%: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $265.49 in the latest trading session, marking a -0.27% move from the prior day.
Here's Why You Should Hold on to LabCorp (LH) Stock For Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) better-than-expected results and robust base business performance.
Walgreens (WBA) Expands Access to COVID-19 Test With LabCorp
by Zacks Equity Research
Walgreens (WBA) will enable more communities to access reliable, convenient testing services as and when required with the addition of Pixel by LabCorp COVID-19 at-home collection kit.
Is John Hancock Multifactor Mid Cap ETF (JHMM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JHMM
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHMM
LabCorp (LH) Expands Clinical Laboratory Services With New Pact
by Zacks Equity Research
LabCorp's (LH) recent collaboration will enable it to administer Ascension's hospital-based laboratories in 10 states and purchase select assets of the health system's outreach laboratory business.
LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
LabCorp (LH) reports better-than-expected results for the fourth quarter, with solid contributions from the Drug Development business driving the top line.